Cascadian Therapeutics, Inc. (CASC) is currently moving with a distance of approximately -11.02% from the 200 day simple moving average and sited a distance of 0.24% from its 20 days moving average and isolated upward from 50 days moving average with 4.88%.
In recent trade check out, shares of Cascadian Therapeutics, Inc. (CASC) are at -63.30% from the 52-week high, and are keeping their distance at 26.73% from 52-week low. Currently, the company ROA is -55.20%. Currently CASC hold up 47.91 million outstanding shares and 47.91 million shares are floated in market.
Cascadian Therapeutics, Inc. (CASC) originated a decreased -0.49% move to mark the closing value at $4.03 on Tuesday. CASC recognized downfall move of -0.98% over prior week however the stock price shaped -6.03% so far this year — still in negative area. The stock lost around -40.27% in last one year. CASC, a “Healthcare stock” with an industry focus on “Biotechnology”.
Cascadian Therapeutics, Inc. (CASC) stock remained 4.74% volatile for the week and 4.98% for the month. The relative strength index (RSI) of the stock is located at 54.58.
Cascadian Therapeutics, Inc. (CASC) has volume of 0.1 million shares and an average trading volume of 0.33 million shares. The volume of the particular stock is the shares bought and sold in a single trading day. The average volume of a stock suggests the liquidity of a particular company. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock.
When applying indicators for technical analysis, traders and investors might want to examine the ATR or Average True Range. The current 14-day ATR for Cascadian Therapeutics, Inc. (CASC) is currently sitting at 0.22. The ATR basically measures the volatility of a stock on a day-to-day basis. The ATR is not considered a directional indicator, but it may reflect the strength of a particular move.
Covering Analysts contributed their current consensus recommendation at 3.00. This recommendation scale grounds between 1 and 5. Analysts offer the company with a rating of 3 would be a sign of a Hold recommendation. Analysts pass on shares a rating of 1 or 2 would be suggesting a Buy. A rating of 4 or 5 would point to a Sell recommendation.